CompanyCCCCNasdaqWatertown, MA

C4 Therapeutics, Inc.

C4 Therapeutics develops small-molecule protein degraders using its TORPEDO platform.

SEC EDGAR ClinicalTrials.gov c4therapeutics.com

8-KSep 25Latest SEC filing

Sep 25Latest story

September 2026

C4 Therapeutics presents cemsidomide biomarker data at IMS Annual Meeting

Sep 25Clinical readoutC4 Therapeutics, Inc.cemsidomide

August 2026

C4 Therapeutics reports Q2 2026 results, cemsidomide trials on track for 2027 data

Aug 11Quarterly updateC4 Therapeutics, Inc.cemsidomide